Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.42 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAD52 | P43351 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657817 | 0.96 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL84808 | 0.96 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL262312 | 0.96 | — | — | |
| SCHEMBL577052 | 0.96 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL577415 | 0.96 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2GAAMAPT | |
| Ammonia Solution, Strong SCHEMBL4249875 | 0.92 | — | — | |
| Iodide SCHEMBL11554007 | 0.92 | CHRNA7 (0.46) | CHRNA7ALDH1A1SMN1; SMN2GAAMAPT | |
| Methylamine SCHEMBL21065237 | 0.88 | GAA (0.46) | CHRNA7ALDH1A1SMN1; SMN2GAAMAPT | |
| Bromide SCHEMBL6660869 | 0.88 | CHRNA7 (0.44) | CHRNA7ALDH1A1SMN1; SMN2GAAMAPT | |
| Hydrochloric Acid SCHEMBL28585027 | 0.87 | CHRNA7 (0.39) | CHRNA7ALDH1A1SMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850294-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2023-12-26 | — | — | US | claimed |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2022-03-17 | — | — | US | claimed |
| US-11185480-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2021-11-30 | — | — | US | claimed |
| US-10688026-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2020-06-23 | — | — | US | claimed |
| US-20200016051-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2020-01-16 | — | — | US | claimed |
| US-20190099335-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY | 2019-04-04 | — | — | US | claimed |
| US-20180200164-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2018-07-19 | — | — | US | claimed |
| US-11850294-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2023-12-26 | — | — | US | disclosed |
| EP-2895323-B1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS CO (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2022-03-17 | — | — | US | disclosed |
| US-11185478-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2021-11-30 | — | — | US | disclosed |
| US-11185479-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3765036-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | Premier Dental Products Company (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10434046-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| WO-2019177927-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190099334-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY | 2019-04-04 | — | — | US | disclosed |
| US-20180200163-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2018-07-19 | — | — | US | disclosed |
| US-20180042826-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY | 2018-02-15 | — | — | US | disclosed |
| US-9814657-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| US-20130011453-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY (US) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688026-B2 | Buffered microencapsulated compositions and methods | LIPA, CHMP4B, APOB | CHRNA7 2150/4885GAA 131/4885HSD11B1 3275/4885 |
| US-11185480-B2 | Buffered microencapsulated compositions and methods | CHMP4B, LIPA, APOB | CHRNA7 2237/4885GAA 221/4885HSD11B1 3371/4885 |
| US-11850294-B2 | Buffered microencapsulated compositions and methods | CHMP4B, LIPA, APOB | CHRNA7 2237/4885GAA 221/4885HSD11B1 3371/4885 |
| US-10434046-B2 | Buffered microencapsulated compositions and methods | LIPA, NEFM, CRYAB | CHRNA7 2812/4885GAA 371/4885HSD11B1 3134/4885 |
| US-20180200163-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | CHRNA7 2480/4885GAA 116/4885HSD11B1 3544/4885 |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | CHMP4B, LIPA, APOB | CHRNA7 2237/4885GAA 221/4885HSD11B1 3371/4885 |
| US-20130011453-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | CHRNA7 2480/4885GAA 116/4885HSD11B1 3544/4885 |
| US-20180200164-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | CHRNA7 2150/4885GAA 131/4885HSD11B1 3275/4885 |
| US-20190099334-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, NEFM, CRYAB | CHRNA7 2812/4885GAA 371/4885HSD11B1 3134/4885 |
| US-11185478-B2 | Buffered microencapsulated compositions and methods | LIPA, CHMP4B, APOB | CHRNA7 2365/4885GAA 98/4885HSD11B1 3551/4885 |
| US-20200016051-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | CHMP4B, LIPA, APOB | CHRNA7 2237/4885GAA 221/4885HSD11B1 3371/4885 |
| US-20180042826-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | CHRNA7 2480/4885GAA 116/4885HSD11B1 3544/4885 |
| US-11185479-B2 | Buffered microencapsulated compositions and methods | LIPA, CHMP4B, CRYAB | CHRNA7 2714/4885GAA 410/4885HSD11B1 3090/4885 |
| US-20190099335-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | CHRNA7 2038/4885GAA 182/4885HSD11B1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.